Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 42 | 2025 | 493 | 10.590 |
Why?
|
| Cognitive Dysfunction | 12 | 2024 | 383 | 3.100 |
Why?
|
| Sleep | 13 | 2025 | 755 | 2.880 |
Why?
|
| Sleep Wake Disorders | 7 | 2025 | 286 | 2.120 |
Why?
|
| Neurodegenerative Diseases | 3 | 2023 | 135 | 1.980 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2024 | 79 | 1.700 |
Why?
|
| Disorders of Excessive Somnolence | 4 | 2021 | 32 | 1.380 |
Why?
|
| Cognition | 6 | 2025 | 1153 | 1.360 |
Why?
|
| REM Sleep Behavior Disorder | 4 | 2023 | 14 | 1.340 |
Why?
|
| Exercise Therapy | 6 | 2024 | 443 | 1.190 |
Why?
|
| Electroencephalography | 5 | 2023 | 423 | 1.070 |
Why?
|
| Brain | 5 | 2025 | 2668 | 0.910 |
Why?
|
| Disease Progression | 9 | 2024 | 2757 | 0.900 |
Why?
|
| Deep Brain Stimulation | 4 | 2025 | 153 | 0.880 |
Why?
|
| Restless Legs Syndrome | 2 | 2021 | 21 | 0.810 |
Why?
|
| Physical Fitness | 1 | 2024 | 209 | 0.780 |
Why?
|
| Subthalamic Nucleus | 4 | 2025 | 72 | 0.780 |
Why?
|
| Aged | 33 | 2025 | 23961 | 0.700 |
Why?
|
| Activities of Daily Living | 4 | 2024 | 413 | 0.640 |
Why?
|
| Middle Aged | 31 | 2025 | 33479 | 0.580 |
Why?
|
| Polysomnography | 3 | 2025 | 185 | 0.570 |
Why?
|
| Pedestrians | 1 | 2017 | 9 | 0.560 |
Why?
|
| Aging | 2 | 2025 | 1864 | 0.550 |
Why?
|
| Humans | 55 | 2025 | 137585 | 0.520 |
Why?
|
| Safety | 1 | 2017 | 338 | 0.480 |
Why?
|
| Glutamate Decarboxylase | 1 | 2016 | 170 | 0.480 |
Why?
|
| Status Epilepticus | 1 | 2016 | 50 | 0.480 |
Why?
|
| Quality of Life | 7 | 2024 | 2892 | 0.430 |
Why?
|
| Anticonvulsants | 1 | 2016 | 217 | 0.420 |
Why?
|
| Male | 34 | 2025 | 67762 | 0.420 |
Why?
|
| Female | 34 | 2025 | 73304 | 0.410 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 413 | 0.410 |
Why?
|
| Case-Control Studies | 6 | 2023 | 3556 | 0.400 |
Why?
|
| Kynurenine | 1 | 2013 | 114 | 0.390 |
Why?
|
| Seizures | 1 | 2016 | 426 | 0.380 |
Why?
|
| Huntington Disease | 2 | 2025 | 57 | 0.380 |
Why?
|
| Exercise | 4 | 2020 | 2057 | 0.370 |
Why?
|
| alpha-Synuclein | 3 | 2021 | 35 | 0.370 |
Why?
|
| Longitudinal Studies | 7 | 2024 | 2844 | 0.360 |
Why?
|
| Neuropsychological Tests | 4 | 2024 | 1023 | 0.350 |
Why?
|
| Depression | 2 | 2018 | 1397 | 0.350 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2021 | 89 | 0.320 |
Why?
|
| Aphasia | 2 | 2021 | 21 | 0.320 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 5472 | 0.310 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 60 | 0.310 |
Why?
|
| Tremor | 3 | 2023 | 65 | 0.310 |
Why?
|
| Goals | 2 | 2020 | 170 | 0.300 |
Why?
|
| Dopamine Agents | 2 | 2019 | 19 | 0.290 |
Why?
|
| Aged, 80 and over | 8 | 2024 | 7635 | 0.270 |
Why?
|
| Oxidative Stress | 1 | 2013 | 1317 | 0.260 |
Why?
|
| Gray Matter | 2 | 2024 | 80 | 0.260 |
Why?
|
| Anxiety | 3 | 2024 | 1035 | 0.250 |
Why?
|
| Phototherapy | 1 | 2025 | 39 | 0.240 |
Why?
|
| Neurological Rehabilitation | 1 | 2025 | 9 | 0.230 |
Why?
|
| Walking | 2 | 2022 | 529 | 0.230 |
Why?
|
| Music Therapy | 1 | 2025 | 25 | 0.230 |
Why?
|
| Magnetoencephalography | 1 | 2025 | 149 | 0.220 |
Why?
|
| Wakefulness | 1 | 2025 | 125 | 0.220 |
Why?
|
| Motor Skills | 1 | 2025 | 97 | 0.220 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 1996 | 0.210 |
Why?
|
| Membrane Potentials | 2 | 2022 | 284 | 0.210 |
Why?
|
| Basal Nucleus of Meynert | 1 | 2023 | 1 | 0.200 |
Why?
|
| Multiple Sclerosis | 2 | 2021 | 455 | 0.200 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 2828 | 0.200 |
Why?
|
| Wavelet Analysis | 1 | 2022 | 7 | 0.190 |
Why?
|
| White Matter | 1 | 2024 | 145 | 0.190 |
Why?
|
| Walking Speed | 1 | 2022 | 46 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2024 | 1710 | 0.180 |
Why?
|
| tau Proteins | 2 | 2019 | 90 | 0.180 |
Why?
|
| Biomarkers | 5 | 2022 | 4149 | 0.180 |
Why?
|
| Phenylalanine | 1 | 2021 | 68 | 0.180 |
Why?
|
| Circadian Rhythm | 1 | 2025 | 468 | 0.180 |
Why?
|
| Carbamates | 1 | 2021 | 50 | 0.170 |
Why?
|
| Stroke | 2 | 2021 | 1120 | 0.170 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2020 | 57 | 0.170 |
Why?
|
| Fear | 1 | 2024 | 338 | 0.170 |
Why?
|
| Machine Learning | 2 | 2023 | 493 | 0.160 |
Why?
|
| Databases, Factual | 2 | 2024 | 1357 | 0.160 |
Why?
|
| Adult | 11 | 2025 | 37929 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3566 | 0.150 |
Why?
|
| Self Report | 2 | 2024 | 827 | 0.150 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2019 | 46 | 0.150 |
Why?
|
| Biological Products | 1 | 2022 | 216 | 0.150 |
Why?
|
| Language Therapy | 1 | 2018 | 7 | 0.140 |
Why?
|
| High-Intensity Interval Training | 1 | 2017 | 25 | 0.140 |
Why?
|
| Substantia Nigra | 1 | 2017 | 57 | 0.140 |
Why?
|
| Vaccines | 1 | 2022 | 406 | 0.140 |
Why?
|
| Prospective Studies | 4 | 2021 | 7604 | 0.130 |
Why?
|
| Treatment Outcome | 4 | 2025 | 10811 | 0.130 |
Why?
|
| Neurologic Examination | 1 | 2017 | 110 | 0.130 |
Why?
|
| Adipose Tissue | 1 | 2021 | 635 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 718 | 0.130 |
Why?
|
| Virtual Reality | 1 | 2017 | 61 | 0.130 |
Why?
|
| Saliva | 1 | 2017 | 242 | 0.120 |
Why?
|
| Mental Health | 1 | 2022 | 726 | 0.120 |
Why?
|
| Attention | 1 | 2017 | 427 | 0.110 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 560 | 0.110 |
Why?
|
| Peptides | 1 | 2019 | 985 | 0.100 |
Why?
|
| Disability Evaluation | 1 | 2015 | 290 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1091 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 2057 | 0.100 |
Why?
|
| Age Factors | 2 | 2017 | 3295 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 5778 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 5131 | 0.080 |
Why?
|
| Prognosis | 1 | 2017 | 4030 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2016 | 1496 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2025 | 956 | 0.070 |
Why?
|
| Cohort Studies | 4 | 2023 | 5742 | 0.070 |
Why?
|
| Young Adult | 3 | 2021 | 13209 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2025 | 78 | 0.060 |
Why?
|
| Functional Laterality | 2 | 2018 | 223 | 0.060 |
Why?
|
| Actigraphy | 1 | 2025 | 110 | 0.060 |
Why?
|
| Loneliness | 1 | 2024 | 45 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 3284 | 0.050 |
Why?
|
| Cytokines | 2 | 2022 | 2085 | 0.050 |
Why?
|
| Fatigue | 1 | 2025 | 329 | 0.050 |
Why?
|
| Affect | 1 | 2024 | 292 | 0.050 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 93 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2024 | 308 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2023 | 295 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2025 | 653 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 80 | 0.040 |
Why?
|
| Levodopa | 1 | 2020 | 30 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2021 | 259 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 558 | 0.040 |
Why?
|
| Clonal Selection, Antigen-Mediated | 1 | 2019 | 4 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2019 | 50 | 0.040 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2019 | 21 | 0.040 |
Why?
|
| Movement | 1 | 2021 | 278 | 0.040 |
Why?
|
| Exercise Test | 1 | 2022 | 625 | 0.040 |
Why?
|
| Phenotype | 2 | 2019 | 3196 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2016 | 15657 | 0.040 |
Why?
|
| Executive Function | 1 | 2023 | 451 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2024 | 1477 | 0.030 |
Why?
|
| Sensation Disorders | 1 | 2017 | 37 | 0.030 |
Why?
|
| Stroke Rehabilitation | 1 | 2018 | 42 | 0.030 |
Why?
|
| Hippocampus | 1 | 2023 | 895 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2019 | 363 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2021 | 1993 | 0.030 |
Why?
|
| Biological Specimen Banks | 1 | 2016 | 102 | 0.030 |
Why?
|
| Internationality | 1 | 2016 | 155 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 2017 | 220 | 0.030 |
Why?
|
| Postural Balance | 1 | 2017 | 215 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 1704 | 0.030 |
Why?
|
| Ataxia | 1 | 2015 | 44 | 0.030 |
Why?
|
| Unemployment | 1 | 2015 | 43 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2018 | 1316 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 2017 | 301 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2017 | 503 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1759 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2017 | 706 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2018 | 752 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2019 | 908 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2013 | 109 | 0.020 |
Why?
|
| Oxygen | 1 | 2018 | 931 | 0.020 |
Why?
|
| Inflammation | 1 | 2024 | 2837 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2021 | 2389 | 0.020 |
Why?
|
| Research | 1 | 2015 | 451 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2019 | 4193 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 547 | 0.020 |
Why?
|
| Neurons | 1 | 2020 | 1590 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1622 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 2074 | 0.020 |
Why?
|
| Prevalence | 1 | 2015 | 2734 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 2035 | 0.020 |
Why?
|
| United States | 1 | 2017 | 14841 | 0.010 |
Why?
|